Dalire - indication - references

Article

REFERENCES:
1. Hurst JR et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. NEJM. 363:12. Sept 16, 2010.
2.Burgel PR, Neseme-Meyer P, Chanez P et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest.
2009;135:975-982.
3. DALIRESP (roflumilast) Prescribing Information. Forest Pharmaceuticals, Inc. St. Louis, MO.
4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated
2010. http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf. Accessed June 12, 2012.

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Orexo Announces Positive Topline Data for Nasal Epinephrine Powder OX640 in People with Allergic Rhinitis / Image credit: ©goanovi/AdobeStock

Orexo Announces Positive Topline Data for Nasal Epinephrine Powder OX640 in People with Allergic Rhinitis

Sydney Jennings
January 10th 2025
Article

Treatments with the investigational rescue medication achieved clinically effective epinephrine levels faster than intramuscular injection.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia / image credit ©Sebastian Kaulitzki/stock.adobe.com

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia

Grace Halsey
January 10th 2025
Article

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Sydney Jennings
October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

FDA to Convene Advisory Committee on Brexpiprazole-Sertraline for Adult PTSD / image credit ©Tada Images - stock.adobe.com

FDA to Convene Advisory Committee on Brexpiprazole-Sertraline for Adult PTSD

Patient Care Editorial Staff
January 10th 2025
Article

The adcomm meeting is expected to happen in the first half of 2025, and means the FDA expects to miss the target PDUFA date.

FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial

FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial

Patient Care Editorial Staff
January 9th 2025
Article

Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.

© 2025 MJH Life Sciences

All rights reserved.